Stock Price Movement and Market Context
On 17 Feb 2026, Abbott India’s share price reached Rs.26006.3, the lowest level recorded in the past 52 weeks. This decline follows a sequence of five consecutive days of losses, although the stock showed a slight gain today, moving in line with the Pharmaceuticals & Biotechnology sector’s performance. Despite this minor uptick, Abbott India remains below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating sustained downward momentum.
In contrast, the Sensex opened flat and has since edged up by 0.02% to 83,291.04 points, remaining 3.44% shy of its 52-week high of 86,159.02. The broader market’s resilience, led by mega-cap stocks, highlights the relative weakness in Abbott India’s share price trajectory.
Financial Performance and Valuation Metrics
Over the last year, Abbott India’s stock has declined by 6.76%, underperforming the Sensex, which has gained 9.60% over the same period. The stock’s 52-week high was Rs.35,921.55, underscoring the extent of the recent price erosion. Despite this, the company’s profits have increased by 14.2% over the past year, reflecting operational growth that has not translated into share price appreciation.
The company’s Price to Book Value stands at a high 14, signalling a very expensive valuation relative to its book value. However, the stock currently trades at a discount compared to its peers’ average historical valuations. The PEG ratio of 2.6 further suggests that the stock’s price growth has not kept pace with earnings growth, indicating a stretched valuation in relation to profitability gains.
Momentum just kicked in! This Small Cap from the Auto - Trucks sector entered our list with explosive short-term signals. Catch the wave while it's still building!
- - Fresh momentum detected
- - Explosive short-term signals
- - Early wave positioning
Operational Efficiency and Turnover Ratios
Abbott India’s inventory turnover ratio for the half-year period stands at 7.16 times, which is the lowest among its recent historical figures. Similarly, the debtors turnover ratio is at 13.24 times, also reflecting a decline in efficiency in managing receivables. These metrics suggest a slower movement of inventory and collections, which may have contributed to the stock’s subdued performance.
Despite these figures, the company maintains a low average debt-to-equity ratio of zero, indicating a conservative capital structure with minimal reliance on debt financing. This financial prudence supports the company’s long-term stability but has not been sufficient to offset the impact of other performance factors on the stock price.
Long-Term Performance and Shareholder Composition
Abbott India has demonstrated strong long-term fundamental strength, with an average return on equity (ROE) of 34.23%. Operating profit has grown at an annual rate of 17.25%, reflecting healthy underlying business growth. However, the stock’s returns have been below par over multiple time horizons, including the last three years, one year, and three months, when compared to the BSE500 index.
The majority of the company’s shares are held by promoters, indicating concentrated ownership. This shareholder structure often provides stability but also means that market movements can be influenced by promoter actions and sentiment.
Holding Abbott India Ltd. from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Recent Rating and Market Sentiment
On 12 Jan 2026, Abbott India’s Mojo Grade was downgraded from Hold to Sell, reflecting a reassessment of the stock’s outlook based on recent performance and valuation metrics. The current Mojo Score stands at 44.0, indicating a cautious stance on the stock within the Pharmaceuticals & Biotechnology sector.
The company’s Market Cap Grade is rated 2, suggesting a relatively modest market capitalisation compared to larger peers. The day’s price change was a marginal increase of 0.60%, which is in line with the sector’s overall movement, but insufficient to reverse the broader downtrend.
Summary of Key Metrics
Abbott India’s stock has experienced a notable decline to Rs.26006.3, its lowest in a year, despite underlying profit growth and strong long-term fundamentals. The stock’s valuation remains elevated with a high Price to Book ratio and PEG ratio, while turnover ratios indicate some softness in operational efficiency. The downgrade in rating and underperformance relative to the Sensex and BSE500 indices underscore the challenges faced by the stock in recent months.
While the broader market and sector have shown resilience, Abbott India’s share price reflects a combination of valuation concerns and relative underperformance that have contributed to its 52-week low.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
